A pivotal single-dose randomised, parallel-group, open-label study to demonstrate bioequivalence of 300mg lamotrigine XR [extended release] relative to 100mg + 200mg lamotrigine XR and to demonstrate lack of food effect on 300mg lamotrigine XR in healthy male and female volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Lamotrigine (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics; Registrational
- Sponsors GlaxoSmithKline
- 04 Jan 2007 New trial record.